The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: Use at an assay dependent dilution. Antibody detection limit dilution: 1/64000.
WB: Use at a concentration of 0.1 - 0.3 µg/ml. Predicted molecular weight: 78 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionDirect ligand for the ERBB4 tyrosine kinase receptor. Binding results in ligand-stimulated tyrosine phosphorylation and activation of the receptor. Does not bind to the EGF receptor, ERBB2 or ERBB3 receptors. May be a survival factor for oligodendrocytes.
Tissue specificityHighly expressed in most regions of the brain with the exception of corpus callosum. Expressed at lower level in testis. Not detected in heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, ovary, small intestine, colon and peripheral blood leukocytes.
Sequence similaritiesBelongs to the neuregulin family. Contains 1 EGF-like domain.
Developmental stageIsoform 3 is expressed in fetal brain but not in other fetal tissues.
DomainThe cytoplasmic domain may be involved in the regulation of trafficking and proteolytic processing. Regulation of the proteolytic processing involves initial intracellular domain dimerization. ERBB receptor binding is elicited entirely by the EGF-like domain.
Post-translational modificationsProteolytic cleavage close to the plasma membrane on the external face leads to the release of the soluble growth factor form. Extensive glycosylation precedes the proteolytic cleavage (By similarity). Isoform 3 is glycosylated.
Cellular localizationSecreted; Cell membrane. Does not seem to be active and Cell membrane. Isoform 3 is also proteolytically released as a soluble form.